Clinical Development of NurOwn®

BrainStorm is proceeding with a randomized, double-blind, placebo-controlled multi-dose Phase 3 trial that is being conducted at multiple U.S. sites

Additional information on the NurOwn® clinical trial development program can be found Here


For information on enrollment in the NurOwn® phase 3 trial contact one of the clinical trial sites for details and screening.


United States, California
University of California Irvine Alpha Stem Cell Clinic Recruiting
Irvine, California, United States, 92697
Contact: Robert Zhou    949-824-3990
Principal Investigator: Namita A. Goyal, MD


United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Taylor J Mezoian    617-643-0312
Principal Investigator: James D Berry, MD


United States, Massachusetts

University of Massachusetts

Worcester, Massachusetts, United States, 01655

Contact: Diane McKenna-Yasek    508-856-4697

Principal Investigator: Robert H Brown, D.Phil. M.D.


United States, California

California Pacific Medical Center (CPM) Research Institute

San Francisco, California, United States, 94118

Contact: Dallas Forshew, RN 415-309-5178

Principal Investigator: Robert G. Miller, MD




Principal Investigator: Merit E. Cudkowicz, MD Massachusetts General Hospital
Principal Investigator: Robert H. Brown, MD, PhD UMass Medical School
Principal Investigator: Anthony J. Windebank, MD Mayo Clinic
Principal Investigator: Namita A. Goyal, MD UC Irvine
Principal Investigator: Robert G. Miller, MD California Pacific Medical Center (CPM) Research Institute


Additional information is posted on identifier (NCT number): NCT03280056.


We have undertaken three clinical trials in ALS to date

In all three trials, the primary endpoints were the safety and tolerability of a single intramuscular, intrathecal or simultaneous intramuscular and intrathecal administration. Key secondary efficacy endpoints included the rate of change in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and in forced vital capacity (FVC) during the post-treatment period compared to a three month pre-treatment run-in period.

View our available results from these studies.